Tissue Regenix Group plc provided revenue guidance for six months ended 30 June 2022. Foe the period, the Group reports that trading in the first half of 2022 continues to be strong and in line with the Board's expectations, as healthcare markets in the United States begin the return to pre-pandemic levels. Group revenues for the Period are expected to be approximately $11.8 million, a 25% increase (27% in constant currency) on the prior year.

The Board remains confident that the Group is on track to meet its expectations for the full year.